Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features
American Journal of Respiratory Cell and Molecular Biology · 2023
DOI: 10.1165/rcmb.2022-0203ma ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2023. Verfasst von Luis Rodriguez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary, Allergy, and Critical Care Medicine Division and. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pulmonary Surfactant-Associated Protein C. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, BLRD VA.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial lung disease. A barrier to developing more effective therapies for IPF is the dearth of preclinical models that recapitulate the early pathobiology of this disease. Intratracheal bleomycin, the conventional preclinical murine model of IPF, fails to reproduce the intrinsic dysfunction to the alveolar epithelial type 2 cell (AEC2) that is believed to be a proximal event in the pathogenesis of IPF. Murine fibrosis models based on SFTPC (Surfactant Protein C gene) mutations identified in patients with interstitial lung disease cause activation of the AEC2 unfolded protein response and endoplasmic reticulum stress—an AEC2 dysfunction phenotype observed in IPF. Although these models achieve spontaneous fibrosis, they do so with precedent lung injury and thus are challenged to phenocopy the general clinical course of patients with IPF—gradual progressive fibrosis and loss of lung function. Here, we report a refinement of a murine Sftpc mutation model to recapitulate the clinical course, physiological impairment, parenchymal cellular composition, and biomarkers associated with IPF. This platform provides the field with an innovative model to understand IPF pathogenesis and index preclinical therapeutic candidates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary, Allergy, and Critical Care Medicine Division and.
- Fibrosis Biology Drug Discovery, Bristol-Myers Squibb, Lawrenceville, New Jersey; and.
- PENN-CHOP Lung Biology Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
- The Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania.
ORCID-Profile: Michael F Beers, Jeremy Katzen
Förderung
- NHLBI NIH HHS
- NIEHS NIH HHS
- BLRD VA
- National Heart, Lung, and Blood Institute
- Department of Veterans Affairs, Australian Government
- Bristol Myers Squibb IDEAL Consortium 2.0
- Pulmonary Fibrosis Foundation
- Parker B Francis Foundation
Zitieren
APA
Rodriguez, L., Tomer, Y., Carson, P., Dimopoulos, T., Zhao, M., Chavez, K., Iyer, S., Huang, L., Ebert, C., Sereda, L., Murthy, A., Trujillo, G., Beers, M. F., & Katzen, J. (2023). Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2022-0203ma
Vancouver
Rodriguez L, Tomer Y, Carson P, Dimopoulos T, Zhao M, Chavez K, et al. Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features. American Journal of Respiratory Cell and Molecular Biology. 2023. doi:10.1165/rcmb.2022-0203ma
BibTeX
@article{Rodriguez2023,
author = {Rodriguez, Luis and Tomer, Yaniv and Carson, Paige and Dimopoulos, Thalia and Zhao, Ming and Chavez, Katrina and Iyer, Swati and Huang, Li and Ebert, Christina and Sereda, Larisa and Murthy, Aditi and Trujillo, Glenda and Beers, Michael F and Katzen, Jeremy},
title = {Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2023},
doi = {10.1165/rcmb.2022-0203ma}
}
EUVIMED